Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 study.
CONCLUSIONS: Low-dose SoluMatrix meloxicam may have a potential role as a new therapeutic option for the management of OA-related pain.
PMID: 26503347 [PubMed - in process]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Acetaminophen | Chronic Pain | Headache | Legislation | Lortab | Meloxicam | Migraine | Mobic | Osteoarthritis | Pain | Pain Management | Research | Study | Universities | Urinary Tract Infections